Clinical Trials

75 enrolled

BreastGynecologic

Inflammation, Primary Ovarian Insufficiency, Triple Negative Breast Neoplasms

NCT07523789 2026-04-13

Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC

201 enrolled

Triple Negative Breast Neoplasms

NCT03586297 2026-03-27

Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

49 enrolled

Triple Negative Breast Neoplasms

NCT06396754 2026-03-27

AIDOBE

50 enrolled

Triple Negative Breast Neoplasms

NCT04068623 2026-03-20

PERCEPTION

90 enrolled

Triple Negative Breast Neoplasms

NCT05404321 2026-03-19

TRIPLEX

163 enrolled

Triple Negative Breast Neoplasms

NCT05742269 2026-03-13

MIMIR-mTNBC

Terminated

3 enrolled

Triple Negative Breast Neoplasms

NCT07084571 2026-03-12

FORTITUDE

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06709651 2026-03-04

MINA

30 enrolled

Triple Negative Breast Neoplasms

NCT07421479 2026-02-19

PDO-Mercurial

50 enrolled

Triple Negative Breast Neoplasms

NCT05914961 2026-02-12

Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer

225 enrolled

Triple Negative Breast Neoplasms

NCT05115474 2026-02-09

Study of Screening Brain MRIs in Stage IV Breast Cancer

170 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07332975 2026-01-12

ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC

77 enrolled

Triple Negative Breast Neoplasms

NCT06774027 2025-12-18

ENCORE

100 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04438681 2025-12-04

INSTIGO

90 enrolled

Triple Negative Breast Neoplasms

NCT07260188 2025-12-03

PDO-Neo01

240 enrolled

Triple Negative Breast Neoplasms

NCT07211451 2025-10-08

Axillary Nodal Burden in HER2+ and TNBC

1,571 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02302742 2025-10-06

PROGECT

1,500 enrolled

BreastGynecologic

Breast Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

NCT03165487 2025-08-22

Comparison of the Breast Tumor Microenvironment

14 enrolled

Triple Negative Breast Neoplasms

NCT07073755 2025-07-18

Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05396612 2025-07-08

Role of the Immune Environment in Response to Therapy in Breast Cancer

300 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07046195 2025-07-01

Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer

250 enrolled

Triple Negative Breast Neoplasms

NCT07018427 2025-06-12

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

70 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06991790 2025-05-28

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

51 enrolled

Triple Negative Breast Neoplasms

NCT06965361 2025-05-16

TIL; PD1; PDL1

54 enrolled

Triple Negative Breast Neoplasms

NCT05877859 2025-05-14

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

10 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06476119 2025-04-23

OPTImaL

490 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06798506 2025-01-29

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer

300 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03981705 2024-12-27

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

8 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06700382 2024-11-25

NeoTNBCX

1,166 enrolled

Triple Negative Breast Neoplasms

NCT04803084 2024-11-20

Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment

Suspended

10 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06692725 2024-11-20

NacTNBC

380 enrolled

Triple Negative Breast Neoplasms

NCT06646263 2024-10-17

Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies

Enrolling by invitation

150 enrolled

Triple Negative Breast Neoplasms

NCT04835597 2024-08-26

Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Terminated

27 enrolled

Triple Negative Breast Neoplasms

NCT05111067 2024-08-21

Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity

120 enrolled

Triple Negative Breast Neoplasms

NCT05169853 2024-08-20

Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer

80 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06448169 2024-06-07

Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer

Hypersensitivity, Triple Negative Breast Neoplasms

NCT06441240 2024-06-04

NEORISK

933 enrolled

Breast Neoplasms, Neoplasm Recurrence, Local, Triple Negative Breast Neoplasms

NCT06418139 2024-05-16

PEMCLOCK

450 enrolled

Triple Negative Breast Neoplasms

NCT06309459 2024-03-13

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma

40 enrolled

Triple Negative Breast Neoplasms

NCT05071677 2023-08-09

Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT05730010 2023-08-03

Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis

289 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03920488 2023-06-28

PERSONA

264 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05916755 2023-06-23

PORTRAIT

100 enrolled

Triple Negative Breast Neoplasms

NCT05910710 2023-06-20

Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

50 enrolled

Triple Negative Breast Neoplasms

NCT05302778 2023-05-25

HERMIONE-10

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05831553 2023-05-06

TIP

100 enrolled

Triple Negative Breast Neoplasms

NCT04365790 2023-03-08

Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma

500 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05750719 2023-03-02

Light-Bright

136 enrolled